Precision Aq - Investor Relations & External Communications company information, Employees & Contact Information

From insight to impact: strengthening stakeholder engagement across the patient journey PMLiVE

Precision AQ: 2025 PharmaLive

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference GlobeNewswire

Precision AQ Expands Powerhouse Access Experience Team (AET) to Tackle Evolving Patient Access Challenges in Rare Disease PR Newswire

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire

EyePoint Announces Participation at Upcoming Investor Conferences EyePoint Pharmaceuticals

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference Sahm

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting FinancialContent

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EyePoint Pharmaceuticals

Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478 Yahoo Finance

Precision AQ Launches Navigator365™ Matrix, an Advanced Platform for Identifying Digital Opinion Leaders to Activate and Amplify Brand Messages PR Newswire

Disc Medicine to Participate in Upcoming Investor Conferences | User | poteaudailynews.com FinancialContent

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities Business Wire

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference EyePoint Pharmaceuticals

Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development Yahoo Finance

MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner Business Wire

Precision Value & Health Unveils New Identity: Precision AQ PR Newswire

MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner Business Wire

EyePoint to Present at Guggenheim SMID Cap Biotech Conference EyePoint Pharmaceuticals

Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum GlobeNewswire

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 EyePoint Pharmaceuticals

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference GlobeNewswire

Precision Value and Health Unveils New Identity: Precision AQ PharmiWeb.com

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) Yahoo Finance

Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases Business Wire

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update Business Wire

EyePoint Pharmaceuticals Announces Participation in Upcoming Investor Conferences Quiver Quantitative

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire

Seismic Therapeutic Appoints Sophie Jones, M.D., as Chief Financial Officer Business Wire

City Therapeutics Expands Executive Team and Board of Directors Business Wire

DE&I in clinical trials: the role of health literacy and AI PMLiVE

City Therapeutics Appoints Andy Orth as Chief Executive Officer Business Wire

MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors Business Wire

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy Business Wire

Contact the Board EyePoint Pharmaceuticals

MPM BioImpact Appoints Michael Ehlers, M.D., Ph.D., Experienced R&D Leader and Accomplished Biotechnology Executive, as Entrepreneur Partner Business Wire

ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis Business Wire

Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer Business Wire

Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline Business Wire

Asher Bio Announces Clinical Supply Agreement to Enable Evaluation of Etakafusp Alfa (AB248) in Combination with Rilvegostomig in a Global Phase 1b/2 Study in Non-Small Cell Lung Cancer (NSCLC) Business Wire

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 | About Us | Oil & Gas Journal FinancialContent

News FinancialContent

New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction FinancialContent